Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
Eur J Cardiothorac Surg. 2014 Jan;45(1):83-9. doi: 10.1093/ejcts/ezt259. Epub 2013 May 17.
In patients with acquired valvar disease, morbidity and mortality rates after tricuspid valve replacement (TVR) are high. However, in adult patients with congenital heart disease, though data concerning outcome after TVR are scarce, even poorer results are suggested in patients with Ebstein anomaly. To investigate the applicability of these results to a broader array of congenital heart disease patients, we report the long-term follow-up of prosthesis-related complications, including re-replacement of patients with a tricuspid valve prosthesis and congenital heart disease.
From the Dutch Congenital Corvitia (CONCOR) registry, we identified 20 patients with a biological or mechanical tricuspid valve prosthesis implanted between 1977 and 2012 (total of 31 prostheses). We analysed the tricuspid valve-related complications and mortality.
Ten patients with a median age of 16.2 years at the time of surgery (interquartile range 13.2-28.2 years) received a bioprosthesis while 10 patients with a median age of 36.4 years (interquartile range 14.0-47.0) at the time of surgery received a mechanical prosthesis (P = 0.28). During a mean follow-up of 14 years, 50% needed a re-replacement because of valve-related complications (e.g. valve degeneration or valve thrombosis). The yearly percentage of patients with valve-related complications was 4.2% in patients with a bioprosthesis and 2.7% in those with a mechanical prosthesis. Within 20 years of implantation, the median duration of event-free survival was significantly shorter in 3 patients with a prosthesis-patient mismatch (PPM; 1.0 year; interquartile range 0.01-2.6), compared with 7 without mismatch (8.0 years; interquartile range 5.1-12.3; P = 0.02).
Compared with previous literature on acquired valvar disease, we found a higher incidence of valve-related complications in patients with congenital heart disease that was unrelated to prosthesis material. Our data suggest that PPM may have a negative effect on the event-free interval.
在获得性瓣疾病患者中,三尖瓣置换术(TVR)后的发病率和死亡率很高。然而,在成人先天性心脏病患者中,尽管有关 TVR 后结果的数据很少,但在埃布斯坦畸形患者中,结果更差。为了将这些结果应用于更广泛的先天性心脏病患者群体,我们报告了与假体相关的并发症的长期随访结果,包括再次更换三尖瓣假体和先天性心脏病患者。
从荷兰先天性心外科学会(CONCOR)登记处,我们确定了 20 名患者在 1977 年至 2012 年期间植入了生物或机械三尖瓣假体(共 31 个假体)。我们分析了三尖瓣相关并发症和死亡率。
10 名患者在手术时的中位年龄为 16.2 岁(四分位距 13.2-28.2 岁),接受了生物假体,而 10 名患者在手术时的中位年龄为 36.4 岁(四分位距 14.0-47.0 岁),接受了机械假体(P = 0.28)。在平均 14 年的随访中,由于瓣膜相关并发症(如瓣膜退化或瓣膜血栓形成),50%的患者需要再次更换。在生物假体组中,每年瓣膜相关并发症的患者比例为 4.2%,在机械假体组中为 2.7%。在植入后 20 年内,3 名假体-患者不匹配(PPM)患者的无事件生存中位时间明显短于 7 名无 PPM 患者(1.0 年;四分位距 0.01-2.6;P = 0.02)。
与获得性瓣疾病的既往文献相比,我们发现先天性心脏病患者的瓣膜相关并发症发生率较高,与假体材料无关。我们的数据表明,PPM 可能对无事件间隔产生负面影响。